Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis

Abstract

BackgroundDespite the promising anticancer efficacy observed in preclinical studies, paclitaxel and tanespimycin (17-AAG) combination therapy has yielded meager responses in a phase I clinical trial. One serious problem associated with paclitaxel/17-AAG combination therapy is the employment of large quantities of toxic organic surfactants and solvents for drug solubilization. The goal of this study was to evaluate a micellar formulation for the concurrent delivery of paclitaxel and 17-AAG in vivo.Methodology/Principal FindingsPaclitaxel/17-AAG-loaded micelles were assessed in mice bearing human ovarian tumor xenografts. Compared with the free drugs at equivalent doses, intravenous administration of paclitaxel/17-AAG-loaded micelles led to 3.5- and 1.7-fold increase in the tumor concentrations of paclitaxel and 17-AAG, respectively, without significant altering drug levels in normal organs. The enhanced tumor accumulation of the micellar drugs was further confirmed by the whole-body near infrared imaging using indocyanine green-labeled micelles. Subsequently, the anticancer efficacy of paclitaxel/17-AAG-loaded micelles was examined in comparison with the free drugs (weekly 20 mg/kg paclitaxel, twice-weekly 37.5 mg/kg 17-AAG). We found that paclitaxel/17-AAG-loaded micelles caused near-complete arrest of tumor growth, whereas the free drug-treated tumors experienced rapid growth shortly after the 3-week treatment period ended. Furthermore, comparative metabolomic profiling by proton nuclear magnetic resonance revealed significant decrease in glucose, lactate and alanine with simultaneous increase in glutamine, glutamate, aspartate, choline, creatine and acetate levels in the tumors of mice treated with paclitaxel/17-AAG-loaded micelles.Conclusions/SignificanceWe have demonstrated in the current wok a safe and efficacious nano-sized formulation for the combined delivery of paclitaxel and 17-AAG, and uncovered unique metabolomic signatures in the tumor that correlate with the favorable therapeutic response to paclitaxel/17-AAG combination therapy.

Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy

“…Thus, the use of nanoparticle-based multidrug codelivery systems has been proposed to overcome undesirable toxicity and MDR in the modern clinical cancer therapy. [13][14][15] To date, among the amounts of drug carriers, polymeric micelles have been widely employed in the development of multidrug co-delivery systems due to many advantages, such as core-shell nanostructures, excellent biocompatibility, biodegradability and versatile chemistry for further functionalization. 16,17 In addition, they are of nanoscopic size and stealthy property.…”

Multidrug PLA-PEG filomicelles for concurrent delivery of anticancer drugs—The influence of drug-drug and drug-polymer interactions on drug loading and release properties

“…Co-incorporation of two or three hydrophobic drugs in micelles has already been reported (Aw et al, 2013;Katragadda et al, 2013;Katragadda et al, 2011). PLA-PEG micelles containing paclitaxel (Ptx), 17-AAG and rapamycin (Rap) known as Triolimus present a 10 to 10,000-fold increase in aqueous solubility of drugs, and display potent cytotoxic synergy in vitro and antitumor activity in vivo Hasenstein et al, 2012).…”

Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice

“…It has often been given by intravenous injection in an organic solvent due to its poor solubility in water and low oral bioavailability, which can cause serious side effects. 9 Therefore, a new method of treatment is needed for this compound to replace the toxic organic solvent.…”